A New Model For A New Era Of Psychedelic Therapy5/2/2022
MAPS Public Benefit Corporation hopes to kick off the next golden age of psychedelic therapy with the potential FDA approval of its MDMA candidate for PTSD.
Are Cannabinoids The Next Blockbuster Drugs? A Q&A With Jazz Pharma’s CEO Bruce Cozadd5/2/2022
A Q&A with Bruce Cozadd, chairman and CEO of Jazz Pharmaceuticals, on the $7.2 billion acquisition, integration, and future of cannabis drug pioneer GW Pharmaceuticals.
Thinking Differently About Rare Disease Therapies4/1/2022
As Ultragenyx continues building its new gene therapy manufacturing facility, CEO and president Dr. Emil Kakkis talks about his unique outlook on the rare disease space.
Who Are The “Right” People?4/1/2022
It always will be important for business leaders to surround themselves with the right people. The thing to remember, however, is that there are many variables to determine who the “right” person is.
A Q&A With A Venture Capitalist/Genetic Medicines Executive4/1/2022
Small biotech companies can improve their fundraising prowess, despite choppy market conditions, by avoiding a few common mistakes. Telling a good story is the first step.